SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : SANGUINE CORP. (SGNC)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Striyker who wrote (2019)6/28/1998 9:06:00 PM
From: jmt  Read Replies (1) of 5402
 
Many of these statements make sense:

Third: Wonder where the money is coming from to pay Battelle?

- I they believe in the technology, financing could be similar to Venture Capital, ie. % of ownership.

Fourth: Would think that SGNC's best bet is for a buyout.

Not necessarily. Once approved, many Biotechs provide a license to an established Pharm to market the product. If a minimal amount of cash is needed for manufacturing, why give up or share the potential revenue.

Fifth: Don't call Baxter or J&J. Biotech is a small world. Many of the scientists working on a blood substitute already know each other. Some may have worked together.

Absolutely. They make so many of these small investments, IR would not even be in the loop.

jmt
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News